Transgene to Present at the Cowen & Company 33rd Annual Healthcare Conference

  Transgene to Present at the Cowen & Company 33rd Annual Healthcare
  Conference

Business Wire

STRASBOURG, France -- February 26, 2013

Regulatory News:

Transgene S.A. (Paris:TNG)(Euronext Paris:FR0005175080) today announced that
Philippe Archinard, Chairman & Chief Executive Officer, will be presenting at
the Cowen & Company Annual Healthcare Conference in Boston on Tuesday, March
5, 2013 at 11:20am, Eastern.

A copy of the management presentation will be accessible by visiting the
Transgene website www.transgene.fr under the "Investor & Media" section.

About Transgene:

Transgene, a member of the Institut Mérieux Group, is a publicly traded French
biopharmaceutical company dedicated to the development of therapeutic vaccines
and immunotherapeutic products in oncology and infectious diseases. Transgene
has four compounds in phase 2 clinical development: TG4010 and Pexa-Vec
(JX594/TG6006) having already completed initial phase 2 trials, TG4001 and
TG4040. Transgene has concluded three strategic agreements for the development
of its immunotherapy products: an option agreement with Novartis for the
development of TG4010 to treat various cancers; an in-licensing agreement with
US-based Jennerex, Inc. to develop and market Pexa-Vec, an oncolytic virus,
and with the EORTC for the development of TG4001 to treat HPV induced head and
neck cancers. Transgene has bio-manufacturing capacities for viral-based
products. Additional information about Transgene is available at
www.transgene.fr.

  Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
   400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405
                    ILLKIRCH GRAFFENSTADEN CEDEX (France)
                         Tél: + 33 (0)3 88 27 91 00

Contact:

Transgene
Stéphane Boissel, +33 (0)3 88 27 91 02
Executive Vice President & CFO
or
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director Investor Relations,
or
MC Services
Raimund Gabriel, +49 89 210 228 30
Shaun Brown, +44 207 148 5998
 
Press spacebar to pause and continue. Press esc to stop.